Plasma Protein Binding

The fraction of a compound bound to proteins in the human blood

NEZU
Biotech GmbH

Dear Client,

first and foremost, thanks for downloading this free resource. All graphics in this report are predictions made by our AI systems. They show the profile of this ADMET endpoint for thousands of marketed drugs. We divided it by indication, and as you can see, it changes a lot from one category to another. Therefore, try to find the closest indication to the compounds you are currently developing.

Plasma protein binding answers what fraction of a compound in plasma is bound to proteins, and what fraction remains unbound? The unbound fraction is available to cross membranes, reach many pharmacological targets, undergo metabolism, and be eliminated. The bound fraction remains in reversible equilibrium with the unbound compound. **Neither high nor low binding is inherently favorable.**

Plasma protein binding is commonly measured by equilibrium dialysis. Human plasma containing the test compound is separated from a protein-free buffer by a semipermeable membrane. Small compound molecules cross the membrane, while plasma proteins cannot. After equilibrium, researchers measure compound concentrations in both compartments, usually by liquid chromatography–tandem mass spectrometry.

The assay represents reversible binding under defined experimental conditions. Albumin binds many acidic, neutral, and lipophilic compounds. Alpha-1-acid glycoprotein often binds basic compounds. Lipoproteins and other plasma components also contribute. But the assay does not reproduce tissue binding, or the full dynamics of a living circulation. Temperature, pH, compound concentration, plasma source, membrane leakage, and nonspecific adsorption all affect the result.

A high binding value means that only a small fraction is unbound at equilibrium. This often reduces the unbound concentration relative to the total plasma concentration. It does not, by itself, prove poor efficacy, or slow clearance. These outcomes depend on intrinsic clearance, tissue binding, permeability, dosing, and target potency.

A low binding value produces a larger unbound fraction. This increases immediate availability for distribution, metabolism, and elimination, but does not guarantee better target exposure or safety.

Plasma protein binding must therefore be interpreted with metabolic clearance, volume of distribution, and transporter activity.

We generated these insights using advanced AI systems designed to analyze complex biotech data and highlight potential trends. While we strive for accuracy, AI models

can occasionally make mistakes or miss context, so please treat these predictions as informative guidelines rather than absolute facts.

This report is provided for general informational and educational purposes only, not for medical diagnosis, treatment decisions, or financial advice. Because individual circumstances and data can vary, we cannot be held responsible for any decisions made or losses incurred based on these predictions.

Now that we got this out of the way, we genuinely hope these results are useful for your research.

Sincerely,

Your friends at Nezu Biotech GmbH.

NEZU
Biotech GmbH

Plasma Protein Binding



Plasma Protein Binding



Plasma Protein Binding









Derived from thousands of marketed drugs

Plasma Protein Binding Rate



Plasma Protein Binding Rate



Plasma Protein Binding Rate









Derived from thousands of marketed drugs